Viread now also approved to treat hepatitis B
The drug is administered as a once-daily tablet.
The anti-HIV drug Viread (tenofovir disoproxil fumarate, Gilead Sciences) has gained a new indication: to treat chronic hepatitis B in adults. Administered as a once-daily tablet, the drug works by blocking an enzyme required by the hepatitis B virus to replicate in liver cells. Hepatitis B is most prevalent among Asian Americans in this country.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Recent Videos
Related Content
